Purpose
|
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. made initial inquiries into the drug, however, in May 1996, they discontinued research, and in June 1997 gave research rights to Titan Pharmaceuticals. Titan then handed over worldwide development, manufacturing and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals announced that the Phase III development rights have been acquired by Vanda Pharmaceuticals. FDA approved on May 9, 2009.
|
Characteristics
|
Tradename: Fanapta, Zomaril Source of Compound: synthetic Target: Adrenergic Receptor agonist ,Dopamine Receptor antagonist Receptor: α-adrenergic receptor,Dopamine receptor Status: USP,
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
97?%
|
Formula
|
C24H27FN2O4
|
Solubility
|
DMSO 27 mg/mL, Water <1 mg="" ml="" <="" td="">
1> |